Department of Thoracic Surgery, Centre Hospitalier Vaudois, Lausanne, Switzerland.
Expert Rev Anticancer Ther. 2012 Apr;12(4):495-503. doi: 10.1586/era.12.21.
Resection of lung metastases from colorectal cancer (CRC) is increasingly performed with a curative intent. This strategy was made possible in the 1990s by the development of new chemotherapeutic approaches, improved surgical techniques and better imaging modalities. However, evidence-based data showing clinical benefits of lung metastasectomy in this setting are nonexistent, and there are no prospective randomized trials to support the routine performance of these procedures for stage IV CRC. Current evidence suggests that resection of pulmonary metastases in combination with new cytotoxic agents, such as oxaliplatin, irinotecan and bevacizumab, may result in prolonged survival for many, and cure for a small minority of CRC patients who experienced tumor spread beyond the limits of the abdomen. This review focuses on the results of surgical management of CRC patients with lung metastases: we report the outcome of published series according to the presence or the absence of liver metastasis (and hepatic resection) prior to lung resection.
结直肠癌（CRC）肺转移灶的切除术目前越来越多地被用于治愈目的。这一策略在 20 世纪 90 年代成为可能，当时出现了新的化疗方法、改进的外科技术和更好的成像方式。然而，在这种情况下，没有基于证据的数据显示肺转移切除术的临床获益，也没有前瞻性随机试验支持对 IV 期 CRC 常规进行这些手术。目前的证据表明，切除肺转移灶结合新的细胞毒性药物（如奥沙利铂、伊立替康和贝伐单抗）可能会延长许多患者的生存时间，并使少数经历腹部以外肿瘤扩散的 CRC 患者得到治愈。这篇综述重点介绍了结直肠癌伴肺转移患者的外科治疗结果：我们根据肺切除术前是否存在肝转移（和肝切除术）报告了已发表系列的结果。
